BR112022019558A2 - Método para tratar uma infecção por vírus hepatotrópico, composição farmacêutica para tratar uma infecção viral hepatotrópica, e, uso de um composto - Google Patents

Método para tratar uma infecção por vírus hepatotrópico, composição farmacêutica para tratar uma infecção viral hepatotrópica, e, uso de um composto

Info

Publication number
BR112022019558A2
BR112022019558A2 BR112022019558A BR112022019558A BR112022019558A2 BR 112022019558 A2 BR112022019558 A2 BR 112022019558A2 BR 112022019558 A BR112022019558 A BR 112022019558A BR 112022019558 A BR112022019558 A BR 112022019558A BR 112022019558 A2 BR112022019558 A2 BR 112022019558A2
Authority
BR
Brazil
Prior art keywords
treat
hepatotropic
compound
pharmaceutical composition
infection
Prior art date
Application number
BR112022019558A
Other languages
English (en)
Inventor
Soong Tai-Sen
Original Assignee
Senhwa Biosciences Inc
Tai Sen Soong
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Senhwa Biosciences Inc, Tai Sen Soong filed Critical Senhwa Biosciences Inc
Publication of BR112022019558A2 publication Critical patent/BR112022019558A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

MÉTODO PARA TRATAR UMA INFECÇÃO POR VÍRUS HEPATOTRÓPICO, COMPOSIÇÃO FARMACÊUTICA PARA TRATAR UMA INFECÇÃO VIRAL HEPATOTRÓPICA, E, USO DE UM COMPOSTO. A presente invenção provê um composto ou um método para tratar uma infecção viral hepatotrópica em um humano, particularmente hepatite B e hepatite D, em que o composto é um certo composto tricíclico.
BR112022019558A 2020-03-30 2021-03-18 Método para tratar uma infecção por vírus hepatotrópico, composição farmacêutica para tratar uma infecção viral hepatotrópica, e, uso de um composto BR112022019558A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063001723P 2020-03-30 2020-03-30
US202063053908P 2020-07-20 2020-07-20
PCT/US2021/022988 WO2021202115A1 (en) 2020-03-30 2021-03-18 Antiviral compounds and method for treating hepatotropic viral infection, particularly hepatitis b and hepatitis d

Publications (1)

Publication Number Publication Date
BR112022019558A2 true BR112022019558A2 (pt) 2022-12-06

Family

ID=77920792

Family Applications (2)

Application Number Title Priority Date Filing Date
BR112022019554A BR112022019554A2 (pt) 2020-03-30 2021-03-18 Método e composição farmacêutica para tratar uma infecção viral por ácido ribonucleico, e, uso de um composto
BR112022019558A BR112022019558A2 (pt) 2020-03-30 2021-03-18 Método para tratar uma infecção por vírus hepatotrópico, composição farmacêutica para tratar uma infecção viral hepatotrópica, e, uso de um composto

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BR112022019554A BR112022019554A2 (pt) 2020-03-30 2021-03-18 Método e composição farmacêutica para tratar uma infecção viral por ácido ribonucleico, e, uso de um composto

Country Status (11)

Country Link
US (2) US20210308137A1 (pt)
EP (2) EP4126845A4 (pt)
JP (2) JP2023520883A (pt)
KR (2) KR20230004550A (pt)
CN (1) CN116075502B (pt)
AU (2) AU2021248867A1 (pt)
BR (2) BR112022019554A2 (pt)
CA (2) CA3179372A1 (pt)
IL (2) IL296924A (pt)
TW (2) TW202203914A (pt)
WO (2) WO2021202115A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102641010B1 (ko) 2023-12-04 2024-02-28 대한민국 실미타세르팁을 유효성분으로 포함하는 중증열성혈소판감소증후군 예방 또는 치료용 약학 조성물

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7956064B2 (en) * 2006-09-01 2011-06-07 Cylene Pharmaceuticals, Inc. Fused tricyclic compounds as serine-threonine protein kinase and PARP modulators
CN101528704B (zh) * 2006-09-01 2014-04-09 生华生物科技股份有限公司 丝氨酸-苏氨酸蛋白激酶和parp调节剂
AU2009219154A1 (en) * 2008-02-29 2009-09-03 Cylene Pharmaceuticals, Inc. Protein kinase modulators
BRPI1016185A2 (pt) * 2009-04-17 2016-04-19 Cylene Pharmaceuticals Inc processo para o tratamento de distúrbios associados à atividade da proteína quinase ck2
CA2774266A1 (en) * 2009-09-16 2011-03-24 Cylene Pharmaceuticals, Inc. Novel tricyclic protein kinase modulators
WO2011063398A1 (en) * 2009-11-23 2011-05-26 Cylene Pharamaceuticals, Inc. Polymorphs and salts of a kinase inhibitor
CN102762208A (zh) * 2009-12-04 2012-10-31 赛林药物股份有限公司 作为ck2抑制剂的吡唑嘧啶和相关杂环
TWI534148B (zh) * 2014-02-13 2016-05-21 生華生物科技股份有限公司 吡唑並嘧啶前藥及其使用方法
CN105457029A (zh) * 2014-09-29 2016-04-06 中国科学院上海巴斯德研究所 抑制酪蛋白激酶2活性在促进i型干扰素表达的应用
AU2021241591A1 (en) * 2020-03-24 2022-10-20 Michael W. BURNET Anti-infective and anti-viral compounds and compositions
WO2021247367A1 (en) * 2020-06-02 2021-12-09 Yale University Compounds and compositions for treating, ameliorating, and/or preventing sars-cov-2 infection and/or complications thereof

Also Published As

Publication number Publication date
IL296927B1 (en) 2025-07-01
CA3179167A1 (en) 2021-10-07
WO2021202115A1 (en) 2021-10-07
CN116075502A (zh) 2023-05-05
JP2023520882A (ja) 2023-05-22
US20210308110A1 (en) 2021-10-07
EP4126846A1 (en) 2023-02-08
BR112022019554A2 (pt) 2022-12-06
CA3179372A1 (en) 2021-10-07
CN116075502B (zh) 2024-04-12
WO2021202114A1 (en) 2021-10-07
TW202203914A (zh) 2022-02-01
US11696911B2 (en) 2023-07-11
EP4126845A4 (en) 2024-05-01
EP4126845A1 (en) 2023-02-08
US20210308137A1 (en) 2021-10-07
AU2021248867A1 (en) 2022-12-01
IL296924A (en) 2022-12-01
IL296927B2 (en) 2025-11-01
IL296927A (en) 2022-12-01
JP2023520883A (ja) 2023-05-22
AU2021249224A1 (en) 2022-12-01
KR20230004550A (ko) 2023-01-06
KR20230004549A (ko) 2023-01-06
TW202203915A (zh) 2022-02-01

Similar Documents

Publication Publication Date Title
MX2021014742A (es) Peptidomimeticos para el tratamiento de infecciones por coronavirus y picornavirus.
BR112022018819A2 (pt) Vacinas contra coronavírus e métodos de uso
BR112022000503A2 (pt) Compostos úteis para tratar infecções por vírus influenza
BR112023020600A2 (pt) Método para tratar ou prevenir uma infecção, e, uso de um composto
MY141003A (en) Materials and methods for treating viral infections with a cysteamine compound
CL2024001582A1 (es) Compuestos terapéuticos para la infección por el virus vih
BR112018075682A2 (pt) inibidores de papd5 e papd7 para tratamento de infecção pela hepatite b
BRPI0511834A (pt) métodos por tratar hepatite c
UY37581A (es) Compuestos para el tratamiento de la infección por virus de la hepatitis b
BR112023002951A2 (pt) Compostos de fosfolipídio e usos destes
BR112018009009A2 (pt) terapia combinada de um inibidor de formação de capsídeo hbv e um interferon
BR112012022311A2 (pt) agentes farmacêuticos de combinação como inibidores da replicação de hcv.
BR112019004560A2 (pt) tratamento combinado com agonista de tlr7 e um inibidor de formação de capsídeo de hbv
MX2022009176A (es) Metodo y composiciones para el tratamiento de infeccion por coronavirus.
MX2022007908A (es) Combinacion farmaceutica de un oligonucleotido terapeutico que actua sobre hbv y un agonista de tlr7 para el tratamiento de hbv.
BR112022016604A2 (pt) Compostos para uso em infecções virais
BR112022020147A2 (pt) Compostos para tratar a doença de huntington
CO2022000270A2 (es) Inhibidores de enzimas
BR112022001025A2 (pt) Inibidores de calicreína plasmática
BR112018015629A2 (pt) ?composto, composição, método para tratar um mamífero infectado com o vírus hiv, e, proteína mutante tripla?
CL2021001976A1 (es) Tratamiento de lesiones cutáneas y prurito en pacientes con prurigo nodular
BR112022002025A2 (pt) Composições e métodos para tratar águas residuais
BR112022019558A2 (pt) Método para tratar uma infecção por vírus hepatotrópico, composição farmacêutica para tratar uma infecção viral hepatotrópica, e, uso de um composto
BR112023026992A2 (pt) Medicamento para o tratamento e/ou prevenção do câncer, agentes que aumentam a eficácia do medicamento em uma composição farmacêutica e método para tratar e/ou prevenir o câncer
BR112023016241A2 (pt) Anticorpos que se ligam ao metapneumovírus, proteínas antigênicas de metapneumovírus e usos dos mesmos

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]